


# Screen-Well™ COMPOUND LIBRARIES



## Chemical Genomics

ICCB Known Bioactives  
Kinase Inhibitors  
Phosphatase Inhibitors  
Protease Inhibitors  
Ion Channel Ligands  
REDOX

## Receptor De-orphaning

Bioactive Lipids  
Endocannabinoids  
Fatty Acids  
Neurotransmitters  
Nuclear Receptor Ligands  
Orphan Ligands

## Drug Repurposing

FDA Approved Drugs

## Natural Products

## Pathway Targeting

Autophagy  
Epigenetics  
Wnt Pathway



**In ITALIA please contact:**

Vinci-Biochem  
Tel +39 0571 568 147  
vb@vincibiochem.it  
www.vincibiochem.it



**NORTH & SOUTH AMERICA**

**Global Headquarters**

Enzo Life Sciences Inc.  
10 Executive Boulevard  
Farmingdale, NY 11735  
Phone: 1.800.942.0430  
Fax: 631.694.7501  
info-usa@enzolifesciences.com

**EUROPE & ASIA**

**Switzerland**

Enzo Life Sciences (ELS) AG  
Industriestrasse 17  
CH-4415 Lausen, Switzerland  
Phone: +41 61 926 8989  
Fax: +41 61 926 8979  
info-ch@enzolifesciences.com

**Benelux**

Enzo Life Sciences BVBA  
Frankrijklei 33 – Bus 31  
BE-2000 Antwerpen, Belgium  
Phone: +32 3 466 0420  
Fax: +32 3 466 0429  
info-be@enzolifesciences.com

**France**

Enzo Life Sciences (ELS) AG  
Branch Office Lyon  
13, avenue Albert Einstein,  
F-69100 Villeurbanne, France  
Phone: +33 472 440 655  
Fax: +33 437 484 239  
info-fr@enzolifesciences.com

**Germany**

Enzo Life Sciences GmbH  
Marie-Curie-Strasse 8  
DE-79539 Lörrach, Germany  
Phone: +49 7621 5500 526  
Toll Free: 0800 664 9518  
Fax: +49 7621 5500 527  
info-de@enzolifesciences.com

**UK & Ireland**

Enzo Life Sciences (UK) LTD.  
Palatine House  
Matford Court  
Exeter EX2 8NL, UK  
Phone: 0845 601 1488 (UK customers)  
Fax: +44 1392 825900 (overseas)  
Fax: +44 1392 825910  
info-uk@enzolifesciences.com

For local distributors and detailed product information visit us online:

**[www.enzolifesciences.com](http://www.enzolifesciences.com)**

*Global Research, Global Reach.™*

<b>CHEMICAL GENOMICS</b>	<b>5</b>
ICCB Known Bioactives Library.....	5
Kinase Inhibitor Library .....	5
Ion Channel Ligand Library .....	5
Protease Inhibitor Library .....	6
Phosphatase Inhibitor Library .....	6
REDOX Library .....	6
<b>RECEPTOR DE-ORPHANING</b>	<b>7</b>
Bioactive Lipid Library .....	7
Orphan Ligand Library .....	8
Endocannabinoid Library .....	8
Fatty Acid Library .....	8
Nuclear Receptor Ligand Library .....	8
Neurotransmitter Library .....	9
<b>DRUG REPURPOSING</b>	<b>10</b>
FDA Approved Drug Library .....	10
<b>NATURAL PRODUCTS</b>	<b>10</b>
Natural Product Library .....	10
<b>PATHWAY TARGETING</b>	<b>11</b>
Autophagy Library .....	11
Epigenetics Library .....	11
Wnt Pathway Library .....	11

# FOCUSED COLLECTION OF UNIQUE COMPOUND LIBRARIES

## Screen-Well™ Compound Libraries complement our wide range of small molecules

Enzo Life Sciences has a long and successful track record in identifying, synthesizing and commercializing known bioactives for use as research tool compounds and in assembling relevant sets of focused compounds for screening.

Our long-standing, flagship Screen-Well™ Compound Library product family offers an easy, ready-to-use alternative for compound screening. Each library includes a unique collection of small molecules including inhibitors, activators and inducers.

The library collections are supplied with a complete documentation set that highlights activity descriptions, plate positions, physical information and a structural database (SD) file for integration into your compound database.

Any compound can be ordered individually in needed volumes. In addition, we can work with you to create a custom library configuration or to find a hard-to-source compound.

### Extensive offering

- Current catalog of over 3,000 stand-alone small molecules including natural products, enzyme inhibitors, receptor ligands, drugs, lipids & fatty acids etc.
- A unique offering of focused compound libraries comprised of FDA-approved compounds, natural products, compounds for receptor de-orphaning, chemical genomics, and pathway targeting.

### Proven and Consistent

- Each Screen-Well™ Library collection incorporates years of scientific expertise resulting in libraries that contain the right compounds in the right combination.
- Synthetic chemistry capability with a staff of organic chemists experienced in diverse synthetic methods and techniques.
- Stringent quality control using state-of-the-art methods.

### Novel

- Libraries are composed of relevant small molecules, frequently including proprietary Enzo compounds.

### Easy and cost-efficient

- All of our libraries come in a ready-to-screen format in biocompatible solvents, no reconstitution needed.
- Ability to rapidly and inexpensively source compounds through a supplier network built over a 25 year history.

### Flexible

- Individual compounds are also available for re-supply.
- Custom chemistry services including development of new synthetic routes for novel molecules to rapidly supply known compounds.
- Ability to supply bulk quantities and custom compounds in the gm to kg scale.



# CHEMICAL GENOMICS

Chemical genomics uses target-specific chemical ligands to modulate and understand the cellular or physiological function of all proteins. Small molecule modulation of cell function offers the advantages of temporal and spatial control not easily achieved with traditional molecular genetic approaches and can provide a first step toward the development of new therapeutic agents. While synthesis of new chemical entities is one aspect of chemical genomics, the development of sophisticated screens employing proteomics and noninvasive imaging techniques has allowed new functions to be ascribed to well-characterized small molecules.

## ICCB KNOWN BIOACTIVES LIBRARY

The Screen-Well™ ICCB Known Bioactives Library of biologically active small organic molecules was developed in cooperation with the Harvard Institute of Chemistry and Cell Biology (ICCB; now the Broad Institute Chemical Biology Program (BCBP) and ICCB-Longwood).

### Library includes:

GPCR ligands	Second messenger modulators
Nuclear receptor ligands	Actin & tubulin modulators
Kinase inhibitors	Protease inhibitors
Ion channel blockers	Gene regulation agents
Lipid biosynthesis inhibitors	Phosphodiesterase inhibitors

Product	Compounds	Product #	Size
ICCB Known Bioactives Library	480	BML-2840-0100	100 µl/well

## KINASE INHIBITOR LIBRARY

The Screen-Well™ Kinase Inhibitor Library contains 80 known kinase inhibitors of well-defined activity. The library is ideal for chemical genomics, assay development or as a reference set for secondary screening.

### Targets include:

BTK	Insulin Receptor	PDGFR
CaM Kinase II	JAK	PKA
CDK	JNK	PKC
CKI & II	MAPK	RAF
EGFR	MEK	SAPK
GSK	MLCK	Src-family
IKK	PI 3-Kinase	VEGFR

Product	Compounds	Product #	Size
Kinase Inhibitor Library	80	BML-2832-0100	100 µl/well
Kinase Inhibitor Library	80	BML-2832-0500	500 µl/well

## ION CHANNEL LIGAND LIBRARY

The Screen-Well™ Ion Channel Ligand Library contains 71 Ion channel agonists and antagonists of well-defined activity. The library is ideal for chemical genomics, assay development or as a reference set for secondary screening.

### Targets include:

Calcium Channels	Potassium Channels
Chloride Channels	Sodium Channels

Product	Compounds	Product #	Size
Ion Channel Ligand Library	71	BML-2805-0500	500 µl/well

For detailed product information visit us online:  
[www.enzolifesciences.com](http://www.enzolifesciences.com)

# CHEMICAL GENOMICS

## PROTEASE INHIBITOR LIBRARY

The Screen-Well™ Protease Inhibitor Library contains 53 known protease inhibitors of well-defined activity. The library is ideal for chemical genomics, assay development and as a reference set for secondary screening.

### Targets include:

ACE	DPPIV	Neutrophil elastase
Aminopeptidase B	Furin	Proteasome
Calpains	Granzyme B	$\gamma$ -Secretase
Caspases	Kallikrein	Thrombin
Cathepsins	MMPs	TPPII

Product	Compounds	Product #	Size
Protease Inhibitor Library	53	BML-2833-0100	100 $\mu$ l/well
Protease Inhibitor Library	53	BML-2833-0500	500 $\mu$ l/well

## PHOSPHATASE INHIBITOR LIBRARY

The Screen-Well™ Phosphatase Inhibitor Library contains 33 known phosphatase inhibitors of well-defined activity. The library is ideal for chemical genomics, assay development and as a reference set for secondary screening.

### Targets include:

Calcineurin (PP2B)	JSP-1	PRL-1
CD45	PP1	PRL-3
CDC25	PP2A	PTEN

Product	Compounds	Product #	Size
Phosphatase Inhibitor Library	33	BML-2834-0100	100 $\mu$ l/well
Phosphatase Inhibitor Library	33	BML-2834-0500	500 $\mu$ l/well

## REDOX LIBRARY

The Screen-Well™ REDOX Library contains 84 compounds with defined prooxidant or antioxidant activity. The library is a useful tool for studying the roles of pro- and antioxidant molecules in cells as well as for use in *in vitro* applications.

### Library includes:

Hydroperoxides	Metal chelators	Lazaroids	
Polyphenolics	Thiols	Radical scavengers	
Glutathione peroxidase mimetics	Thiol traps	SOD mimetics	... and more

Product	Compounds	Product #	Size
REDOX Library	84	BML-2835-0100	100 $\mu$ l/well
REDOX Library	84	BML-2835-0500	500 $\mu$ l/well

# RECEPTOR DE-ORPHANING

The Enzo Life Sciences Screen-Well™ Libraries are ideal tools for receptor de-orphaning approaches. The Screen-Well™ Libraries for receptor de-orphaning include plates of bioactive lipids, endocannabinoids, fatty acids, neurotransmitters, nuclear receptor ligands, and orphan ligands, compounds with defined or speculative biological activity but whose binding partner has not been identified. Each compound is dissolved in a biocompatible solvent and aliquoted to a 96-well plate. This format, together with the focus of each library on a defined group of ligands, make the Screen-Well™ Libraries convenient and cost-effective collections of related compounds suitable for performing individual assays or high-throughput screening.

## Ligands of recently de-orphaned GPCRs found in Enzo Life Sciences Screen-Well™ Libraries

Orphan Receptor(s)	Ligand	Function	Library	Reference
ORL-1	Nociceptin/Orphanin FQ	Pain, Anxiety, Memory	BML-2814	11,12
OGR-1	Sphingosylphosphorylcholine	Proliferation	BML-2800	13
HG57(Cys-LT1R)	Leukotriene D <sub>4</sub>	Bronchial constriction	BML-2800	14
PSECO146(Cys-LT2R)	Leukotriene C <sub>4</sub> , D <sub>4</sub>	Bronchial constriction	BML-2800	15,16
BLT1,2	Leukotriene B <sub>4</sub>	Bronchial constriction	BML-2800	17-20
Edg1,3,5,6,8	Sphingosine-1-phosphate	Cell differentiation, growth	BML-2800	21-25
Edg2,4,7	Lysophosphatidic Acid	Cell differentiation, growth	BML-2800	26-29
TA1, TA2	Trace Amines (tyramine)	Unknown	BML-2825	10
CRTH2	Prostaglandin D <sub>2</sub>	Vasodilation, immunity, sleep	BML-2800	30
GPR3,6,12	Sphingosine-1-phosphate	Cell differentiation, growth	BML-2800	31
TG1019/OXE	5-Oxe-EETE (5-KETE)	Eosinophil activation	BML-2800	32
GPR40	Fatty Acids	Insulin secretion	BML-2803	33
GPR119	Oleylethanolamide	Satiety	BML-2800	34
GPR18	N-Arachidonylglycine	Unknown	BML-2800	35
G2A	9-HODE	Lymphocyte homeostasis	BML-2800	36
GPR35	Kynurenic acid	Unknown	BML-2817	37
GPR109B	D-Phenylalanine	Leukocyte chemoattractant	BML-2825	38

### REFERENCES

- |   |  |  |   |
|---|--|--|---|
| [1] D.Y. Oh; <i>Int. Rev. Cytol.</i> 252, 163 (2006)                      | [11] R.K. Reinscheid <i>et al.</i> ; <i>Science</i> 270 792, (1995)        | [21] J. R. Van Broeklyn <i>et al.</i> ; <i>J. Biol. Chem.</i> 274, 4626 (1999) | [31] K. Uhlenbrock <i>et al.</i> ; <i>Cellular Signaling</i> 14, 941 (2002)         |
| [2] Y. Saito <i>et al.</i> ; <i>Nature</i> 400, 265 (1999)                | [12] J. C. Meunier <i>et al.</i> <i>Nature</i> 377, 532 (1995)             | [22] Y. Yamazaki <i>et al.</i> ; <i>BBRC</i> 268, 583 (2000)                   | [32] T. Hosoi <i>et al.</i> ; <i>J. Biol. Chem.</i> 277, 31465 (2002)               |
| [3] Y. Shimomura <i>et al.</i> ; <i>BBRC</i> 261, 622 (1999)              | [13] Y. Xu <i>et al.</i> ; <i>Nat. Cell Biol</i> 2, 261 (2000)             | [23] H. Okamoto <i>et al.</i> ; <i>BBRC</i> 260, 203 (1999)                    | [33] C.P. Briscoe <i>et al.</i> ; <i>J. Biol. Chem.</i> 278, 11303 (2003)           |
| [4] H.P. Nothacker <i>et al.</i> ; <i>Nature Cell Biol.</i> 1, 383 (1999) | [14] K.R. Lynch <i>et al.</i> ; <i>Nature</i> 399, 789 (1999)              | [24] S. An <i>et al.</i> ; <i>J. Biol. Chem.</i> 275, 288 (2000)               | [34] H. Overton <i>et al.</i> ; <i>Cell Metab.</i> 3, 167 (2006)                    |
| [5] M. Mori <i>et al.</i> ; <i>BBRC</i> 265, 123 (1999)                   | [15] C.E. Heise <i>et al.</i> ; <i>J. Biol. Chem.</i> 275 30531 (2000)     | [25] D. S. Im <i>et al.</i> ; <i>J. Biol.Chem.</i> 275, 14281 (2000)           | [35] M. Kohno <i>et al.</i> ; <i>Biochem. Biophys. Res. Commun.</i> 347, 827 (2006) |
| [6] O. Civelli; <i>Trends Neurosci.</i> 24, 230 (2001)                    | [16] H.P. Nothacker <i>et al.</i> ; <i>Mol. Pharmacol.</i> 58, 1601 (2000) | [26] D. S. Im <i>et al.</i> ; <i>Mol. Pharmacol.</i> 57, 57 (2000)             | [36] H. Obinata <i>et al.</i> ; <i>J. Biol. Chem.</i> 280, 40676 (2005)             |
| [7] T. Hla; <i>Science</i> 294, 1781 (2001)                               | [17] Y. Tryselius <i>et al.</i> ; <i>BBRC</i> 274, 377 (2000)              | [27] N. Fukushima <i>et al.</i> ; <i>PNAS</i> 95 6151 (1998)                   | [37] J. Wang <i>et al.</i> <i>J. Biol. Chem.</i> 281, 22021 (2006)                  |
| [8] E. Kostenis; <i>Pharmacol. Ther.</i> 102, 243 (2004)                  | [18] M. Kamohara <i>et al.</i> ; <i>J. Biol. Chem.</i> 275, 27000 (2000)   | [28] J. R. Erickson <i>et al.</i> ; <i>J. Biol. Chem.</i> 273, 1506 (2000)     | [38] Y. Inukayama-Tomobe <i>et al.</i> ; <i>PNAS</i> 106, 3930 (2009)               |
| [9] J.K. Chambers <i>et al.</i> ; <i>J. Biol. Chem.</i> 275 10767 (2000)  | [19] S. Wang <i>et al.</i> ; <i>J. Biol. Chem.</i> 275, 40686 (2000)       | [29] S. An <i>et al.</i> ; <i>J. Biol. Chem.</i> 273, 7906 (2000)              |   |
| [10] B. Borowsky <i>et al.</i> ; <i>PNAS</i> 98 8966 (2001)               | [20] M. J. Lee <i>et al.</i> ; <i>Science</i> 279, 1552 (1998)             | [30] H. Hirai <i>et al.</i> ; <i>J. Exp. Med.</i> 193, 255 (2001)              |   |

## BIOACTIVE LIPID LIBRARY

The Screen-Well™ Bioactive Lipid Library contains 195 bioactive lipids aliquoted to 3 x 96-well plates. Ideal for screening or identifying orphan G protein-coupled receptors (GPCR's) and nuclear receptors. Also useful for assay development, secondary screening and other pharmacological applications.

### Library includes:

Agonists & antagonists	LPA & phosphatidic acids
Cannabinoids	Octadecanoids
Farnesyl/geranylgeranyl derivatives	PAFs
HETEs, deHETEs and hepxilins	Prostaglandins & thromboxanes
Polyunsaturated fatty acids	Retinoids and vitamin D metabolites
Leukotrienes and lipoxins	Sphingolipids

Product	Compounds	Product #	Size
Bioactive Lipid Library	195	BML-2800-0100	100 µl/well
Bioactive Lipid Library	195	BML-2800-0500	500 µl/well

For detailed product information visit us online:  
[www.enzolifesciences.com](http://www.enzolifesciences.com)

# RECEPTOR DE-ORPHANING

## ORPHAN LIGAND LIBRARY

The Screen-Well™ Orphan Ligand Library contains 84 compounds with defined, putative, potential or speculative activity but whose protein binding partners have not been identified. The library is a rich source of potential ligands for receptor de-orphaning.

### Library includes:

D-Amino acid derivatives	Neurotransmitter metabolites	Nicotine congeners	Endo-Alkaloids
Endogenous $\beta$ -carbolines	Novel Actives	Urinary metabolites	
Product	Compounds	Product #	Size
Orphan Ligand Library	84	BML-2825-0500	500 $\mu$ l/well

## ENDOCANNABINOID LIBRARY

The Screen-Well™ Endocannabinoid Library contains 60 compounds with defined, putative, potential or speculative activity at cannabinoid (CB) receptors and TRPV channels. The library is an array of 10 different fatty acids and 6 different polar head groups. The library is a source of known and novel compounds for receptor de-orphaning, assay development and as a reference set for secondary screening.

### Library includes:

Acyl-dopamines	Acyl-GABAs	Amides	Ethanolamides	Lipo-amino acids
Product	Compounds	Product #	Size	
Endocannabinoid Library	60	BML-2801-0100	100 $\mu$ l/well	
Endocannabinoid Library	60	BML-2801-0500	500 $\mu$ l/well	

## FATTY ACID LIBRARY

The Screen-Well™ Fatty Acid Library contains 68 fatty acids of varying saturation and chain length. Many free fatty acids and their metabolites serve as precursors to important signaling systems (e.g. prostaglandins), act directly as receptor ligands or enzyme inhibitors, and have pre- or anti-atherosclerotic and anti-hypertensive properties through mechanisms that are still being characterized. Therefore, a diverse set of fatty acids can be a rich source of compounds for receptor de-orphaning, inhibitor screening, and high content screening. This set contains both fatty acids with defined activities and fatty acids with putative biological activities.

### Library includes:

Unsaturated & saturated fatty acids	C10-24 chain length	E and Z isomers	Arachidonic acid	Linolenic acid	$\gamma$ -Linolenic acid
Product	Compounds	Product #	Size		
Fatty Acid Library	68	BML-2803-0100	100 $\mu$ l/well		
Fatty Acid Library	68	BML-2803-0500	500 $\mu$ l/well		

## NUCLEAR RECEPTOR LIGAND LIBRARY

The Screen-Well™ Nuclear Receptor Ligand Library contains 76 compounds with defined, putative and potential activity at nuclear receptors. Receptor agonists and antagonists are included. The library is an ideal tool for receptor de-orphaning, assay development and other pharmacological applications.

### Targets include:

AHR	PXR	FXR	ER	LXR	VDR	RXR	CAR	PPAR	RAR
Product	Compounds	Product #	Size						
Nuclear Receptor Ligand Library	76	BML-2802-0100	100 $\mu$ l/well						
Nuclear Receptor Ligand Library	76	BML-2802-0500	500 $\mu$ l/well						

## NEUROTRANSMITTER LIBRARY

The Screen-Well™ Neurotransmitter Library contains 651 CNS receptor ligands, including endogenous neurotransmitters, agonists, antagonists and drugs in a 96-well format. The library is ideal for screening orphan G protein-coupled receptors, target validation, secondary screening, assay development, and for other pharmacological applications. The library contains 13 classes of ligands in 10 deep-well plates. Plates are available individually or as a complete set.

### Library includes:

Adrenergics	GABAergics	Serotonergics	Purinergics
Cholinergics	Ionotropic glutamatergics	Histaminergics (& melatonin ligands)	
Dopaminergics	Metabotropic glutamatergics	Opioids (& sigma ligands)	

Product	Compounds	Product #	Size
Neurotransmitter Library (10-plate set)	651	BML-2810-0100	100 µl/well
Neurotransmitter Library (10-plate set)	651	BML-2810-0500	500 µl/well
Adrenergics	83	BML-2811-0100	100 µl/well
Adrenergics	83	BML-2811-0500	500 µl/well
Dopaminergics	81	BML-2812-0100	100 µl/well
Dopaminergics	81	BML-2812-0500	500 µl/well
Serotonergics	79	BML-2813-0100	100 µl/well
Serotonergics	79	BML-2813-0500	500 µl/well
Opioids (& Sigma Ligands)	75	BML-2814-0100	100 µl/well
Opioids (& Sigma Ligands)	75	BML-2814-0500	500 µl/well
Cholinergics	73	BML-2815-0100	100 µl/well
Cholinergics	73	BML-2815-0500	500 µl/well
Histaminergics (& Melatonin Ligands)	41	BML-2816-0100	100 µl/well
Histaminergics (& Melatonin Ligands)	41	BML-2816-0500	500 µl/well
Ionotropic Glutamatergics	61	BML-2817-0100	100 µl/well
Ionotropic Glutamatergics	61	BML-2817-0500	500 µl/well
Metabotropic Glutamatergics	51	BML-2818-0100	100 µl/well
Metabotropic Glutamatergics	51	BML-2818-0500	500 µl/well
GABAergics	56	BML-2819-0100	100 µl/well
GABAergics	56	BML-2819-0500	500 µl/well
Purinergics (& Adenosines)	51	BML-2820-0100	100 µl/well
Purinergics (& Adenosines)	51	BML-2820-0500	500 µl/well

For detailed product information visit us online:  
[www.enzolifesciences.com](http://www.enzolifesciences.com)

# DRUG REPURPOSING

In addition to classic methods of drug discovery, drug repositioning or repurposing can be an important supplemental pathway for the discovery of new therapies.

## FDA APPROVED DRUG LIBRARY

The Screen-Well™ FDA Approved Drug Library contains 640 FDA approved drugs, carefully selected to maximize chemical and pharmacological diversity. The library contains clinically-relevant pharmacophores for SAR or toxicity studies and provides an ideal starting point for drug repurposing or repositioning programs.

### Library includes:

Analgesics	Antineoplastics	Antiacnes	Anticholinergics
Antibacterials	Anticholinergics	Anticonvulsants	Antidepressants
Antihistaminergics	Atihyperlipidemics	Anti-inflammatories	Antimalarials
Antiprotozoals	Antipsychotics	Adrenergics	Bronchodilators
COX2 Inhibitors	LO inhibitors	Erectile dysfunction	Estrogens
Muscle relaxants	Vasoconstrictors	Antihypertensives	Anthelmintics
Antiarrhythmics	Antiasthmatics	Anticholinesterases	Anticoagulants
Antidiabetics	Antifungals	Antihypertensives	Antiinfectants
Antiparasitics	Antiplatelet	Antiulceratives	Antivirals
Chelating agents	Cholinergics	Antiarthritics	Diuretics
Glucocorticoids	Antihistamines	Vasodilators	Vitamins

Product	Compounds	Product #	Size	Format
FDA Approved Drug Library	640	BML-2841-0100	100 µl/well	2 mg/ml
FDA Approved Drug Library	640	BML-2841-0500	500 µl/well	2 mg/ml
FDA Approved Drug Library	640	BML-2842-0100	100 µl/well	10mM
FDA Approved Drug Library	640	BML-2842-0500	500 µl/well	10mM

# NATURAL PRODUCTS

## NATURAL PRODUCT LIBRARY

Natural products are an unsurpassed source of chemical diversity and are an ideal starting point for any screening program in the search for pharmacologically active small molecules. The Natural Product Library contains over 500 well-characterized natural products which are available in mg to gram quantities. The entire Screen-Well™ collection is available from stock at 1 mg per compound. Quantities greater or less than 1 mg or subsets are available as custom libraries.

### Library includes:

Terpenoids	Peptolides	Flavones	Coumarins
Alkaloids	Macrolides	Isoflavones	Synthetic derivatives

Product	Compounds	Product #	Size
Natural Product Library	502	BML-2865-0100	100 µl/well
Natural Product Library	502	BML-2865-0500	500 µl/well

# PATHWAY TARGETING

One approach in drug discovery is to target a signaling pathway known to be involved in a disease, rather than aiming at a single target. Toward that end, Enzo Life Sciences offers a growing line of Pathway Targeting libraries.

## AUTOPHAGY LIBRARY

The Screen-Well™ Autophagy Library contains 97 compounds with defined autophagy-inducing or -inhibitory activity. Compounds are dissolved in DMSO at 10mM or 1 mM and aliquoted into deep-well plates at 100 or 500µl per well. A variety of structurally and mechanistically different compound classes are included. The library is a useful tool for studying the roles of pro- and anti-autophagic molecules in cells as well as for use in *in vitro* applications.

### Targets include:

Heat shock	ER stress	mTOR/PI3K	Calcium channels	Epigenetics
cAMP	Proteasome	Cytoskeleton	Select kinases	... and more

Product	Compounds	Product #	Size
Autophagy Library	97	BML-2837-0100	100 µl/well
Autophagy Library	97	BML-2837-0500	500 µl/well

## EPIGENETICS LIBRARY

The Screen-Well™ Epigenetics Library contains 43 compounds with defined epigenetics-related activity. Compounds are dissolved in DMSO at 10mM and aliquoted into deep-well plates at 100 or 500µl per well. A variety of structurally and mechanistically different compound classes are included. The library is a useful tool for chemical genomics, assay development, and other pharmacological applications.

### Targets Include:

HDACs	HATs	SIRT5	Lysine demethylases	Histone methyltransferases	DNA methyltransferases
-------	------	-------	---------------------	----------------------------	------------------------

Product	Compounds	Product #	Size
Epigenetics Library	43	BML-2836-0100	100 µl/well
Epigenetics Library	43	BML-2836-0500	500 µl/well

## WNT PATHWAY LIBRARY

The Screen-Well™ Wnt Pathway Library contains 75 compounds with defined activity on the Wnt pathway. A variety of structurally and mechanistically different compound classes are included. The library is a useful tool for chemical genomics, assay development, and other pharmacological applications.

### Targets Include:

Wnt5a	DKK	Porcupine	β-catenin	sFRP1	TCF
GSK3β	Adenylate cyclase	COX2	Dishevelled	Axin	LRP5/6

Product	Compounds	Product #	Size
Wnt Pathway Library	75	BML-2838-0100	100 µl/well
Wnt Pathway Library	75	BML-2838-0500	500 µl/well

### Selected Compound Library Literature Citations

#### BML-2800 Bioactive Lipids Library

1. I. Martins et al.; *Oncogene* 30, 1147 (2010)
2. P. Stoilov et al.; *PNAS* 105, 11218 (2008)

#### BML-2801 Endocannabinoid Library

1. P. Stoilov et al.; *PNAS* 105, 11218 (2008)

#### BML-2805 Ion Channel Ligand Library

1. P. Stoilov et al.; *PNAS* 105, 11218 (2008)

#### BML-2810 Neurotransmitter Library

1. S.Y. Shaw et al.; *PNAS* 108, 492 (2010)

#### BML-2825 Orphan Ligand Library

1. P. Stoilov et al.; *PNAS* 105, 11218 (2008)

#### BML-2832 Kinase Inhibitor Library

1. Y. Gao et al.; *J. Neurochem.* 113, 1331 (2010)
2. M.R. Mand et al.; *J. Biomol. Screen.* 15, 434 (2010)
3. K.J. Leuchowius et al.; *Mol. Cell. Proteomics* 9, 178 (2010)

#### BML-2833 Protease Inhibitor library

1. H.H. Cheung et al.; *Cell Death Dis.* 2, e146 (2011)

#### BML-2840 ICCB Known Bioactives Library

1. S.Y. Shaw et al.; *PNAS* 108, 492 (2010)
2. J. Schulte et al.; *PLoS ONE* 6, e23841 (2011)
3. X. Charpentier et al.; *PLoS Pathogens* 5, e10000501 (2009)
4. S.M. Corsello et al.; *Blood* 113, 6193 (2009)

#### BML-2841 FDA Approved Library

1. F. Halley et al.; *J. Biomol. Screen.* ePub (2011)
2. B. Chen et al.; *Int. J. High Throughput Screen.* 1, 49 (2010)

For detailed product information visit us online:  
**www.enzolifesciences.com**



**GLOBAL HEADQUARTERS**

Enzo Life Sciences Inc.  
10 Executive Boulevard  
Farmingdale, NY 11735  
Phone: 1.800.942.0430  
Fax: 631.694.7501  
info-usa@enzolifesciences.com

**EUROPE/ASIA**

Enzo Life Sciences (ELS) AG  
Industriestrasse 17  
CH-4415 Lausen, Switzerland  
Phone: +41 61 926 8989  
Fax: +41 61 926 8979  
info-eu@enzolifesciences.com

For local distributors and detailed product information visit us online:  
**[www.enzolifesciences.com](http://www.enzolifesciences.com)**